Predict your next investment

Cambridge Cancer Genomics company logo
HEALTHCARE | Biotechnology
ccg.ai

See what CB Insights has to offer

Founded Year

2016

Stage

Acquired | Alive

Total Raised

$4.67M

About Cambridge Cancer Genomics

Cambridge Cancer Genomics uses artificial neural networks and machine learning algorithms to design personalized tests for tracking treatment response in cancer patients. By applying its proprietary analysis to a tumor's genomic features, it can follow the progress of a treatment course through a blood sample.On June 23, 2021, Cambridge Cancer Genomics was acquired by Dante Labs. The terms of the transaction were not disclosed.

Cambridge Cancer Genomics Headquarter Location

72 Hills Road

Cambridge, England, CB2 1LA,

United Kingdom

Latest Cambridge Cancer Genomics News

Dante Labs acquires CCG.ai to build precision oncology software

Jun 25, 2021

This week, the company acquired Cambridge Cancer Genomics (CCG.ai), a leader in machine learning for clinical oncology. It now aims to create a … Welcome to the home of information resources for AI and ML. We hope you find this site useful. Feel free to give us feedback. Copyright © 2020 Informed AI Group Ltd - Neurons.AI - The home of AI information resources This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More Privacy & Cookies Policy

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cambridge Cancer Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cambridge Cancer Genomics is included in 5 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

7,904 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

11,292 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Cambridge Cancer Genomics Patents

Cambridge Cancer Genomics has filed 1 patent.

The 3 most popular patent topics include:

  • Artificial neural networks
  • Genetics
  • Machine learning
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/24/2020

Artificial neural networks, Machine learning, Molecular biology, Genetics, Rare diseases

Application

Application Date

1/24/2020

Grant Date

Title

Related Topics

Artificial neural networks, Machine learning, Molecular biology, Genetics, Rare diseases

Status

Application

Cambridge Cancer Genomics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cambridge Cancer Genomics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.